Navigation Links
ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders
Date:9/6/2010

sented at EURETINA Highlight the Attractive Characteristics of this Novel Potential Treatment Option for Retinal Disorders

ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France. The MIVI-TRUST program is the largest interventional clinical program ever performed to specifically evaluate the vitreoretinal interface in patients with retinal disorders, recruiting a total of 652 patients at 90 centers across the U.S. and Europe.

The pooled results of the TG-MV-006 and TG-MV-007 Phase III trials were presented by Prof. Peter Stalmans (University Hospitals Leuven, Belgium). These results demonstrate the potential of microplasmin to transform the treatment of a range of retinal disorders.

The Phase III program showed that microplasmin: - Was successful in resolving vitreomacular adhesion (VMA) - Was able to cure full thickness macular hole (FTMH) without the need for surgery - Delivered an improvement in the vision of patients without the need for surgery - Was safe and well tolerated

Both the TG-MV-006 and TG-MV-007 trials met the primary endpoint, achieving a statistically significant improvement in the resolution of VMA. The pooled results from the MIVI-TRUST program showed that 26.4% of the 465 microplasmin treated patients achieved resolution of their VMA at 28 days, compared to 10.2% of the 182 patients who received a placebo injection, a highly statistically significant result (p=0.000002).

In patients without epiretinal membrane, microplasmin was shown to be even more effective, with 37.4% of 270 patients achieving nonsurgical resolution of their VMA at 28 days, compared to 14.3% of 119 placebo
'/>"/>

SOURCE ThromboGenics NV
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
4. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
7. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
8. ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
9. ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
10. ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
11. ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... PHILADELPHIA , Aug. 21, 2014  ACI ... platform for independent Data Monitoring Committees. ... to 30 percent over industry standard costs and ... an industry leader in committee services. ... member recruitment and contracting, charter development, statistical programming ...
(Date:8/21/2014)... PARK, N.J. , Aug. 21, 2014 /PRNewswire/ ... pharmacy group purchasing organization (GPO), is pleased to ... to collaborate on a host of innovative specialty ... help Aurora deliver enhanced therapy management services to ... Management (OTM) system. Aurora will use ...
(Date:8/21/2014)... 21, 2014  The board of directors of VirtualScopics, ... of clinical trial imaging solutions, today announced that ... officer, effective immediately.  Mr. Groff has held the role ... joined VirtualScopics in January 2006 as an accounting manager ... "When the board of VirtualScopics asked Jim to ...
Breaking Medicine Technology:ACI Clinical: Innovation and Savings in Data Safety Monitoring Committees 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 4
... BILLERICA, Mass., Sept. 15 HydroCision Inc. ( ... announced today the purchase of the majority of ... capital firms Volcano Capital, Bioventures, and Omega Funds. ... SpineJet®, whose innovative Fluidjet surgical technology allows discectomy ...
... VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the ... the treatment of cancer, respiratory and inflammatory diseases, announced ... FierceBiotech "Fierce 15" list, designating it as one of ... industry. Every year, FierceBiotech evaluates hundreds of private companies, ...
Cached Medicine Technology:HydroCision Announces New Investment to Accelerate Growth of Novel Fluidjet Technology for Minimally Invasive Spine Surgery 2FierceBiotech Names VentiRx Pharmaceuticals as One of the 'Fierce 15' Biotech Companies of 2010 2
(Date:8/21/2014)... 21, 2014 Today, Zane Benefits, the ... the premium tax credits in 2015. , According to ... part of the Affordable Care Act (ACA), premium tax ... individual health insurance through the Health Insurance Marketplaces. , ... and the amount of the tax credits, updated for ...
(Date:8/21/2014)... MI (PRWEB) August 21, 2014 An ... informing a taxpayer that their federal tax payment is ... domain appears to come from the IRS, “tax@irs.gov”, it’s ... to provide personal and financial information. , While similar ... now, an uptick in phishing activity is occurring right ...
(Date:8/21/2014)... heart-lung support technology, the University of Michigan,s Transplant Center ... and pancreases available for transplant by about 20 percent. ... Transplantation and detail the impact of more than ... to improve the quality and viability of organs donated ... limited by the number of donated organs available, so ...
(Date:8/21/2014)... to exercise is a challenge. Thankfully, there are Zombies chasing ... of more than 31,000 health and fitness apps on the ... that use games to increase physical activity. , Gamification is ... to cash in to help people get fit. Whether or ... seen. , "It,s just been assumed that gamified apps will ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Pulmonary ... with an Education Forum for PH patients and ... Who:    The Pulmonary Hypertension Association – the ... find ways to prevent and cure pulmonary hypertension ... affects the functioning of the heart and can ...
Breaking Medicine News(10 mins):Health News:Beware Of Phony “Tax Payment Rejected” IRS Emails 2Health News:Extracorporeal support can significantly increase number of organs for transplant 2Health News:Playing hunger games: Are gamified health apps putting odds in your favor? 2Health News:Pulmonary Hypertension Association Goes On the Road to Houston With an Education Forum for PH Patients and Families to Help Fight Rare Lung Disease 2Health News:Pulmonary Hypertension Association Goes On the Road to Houston With an Education Forum for PH Patients and Families to Help Fight Rare Lung Disease 3
... , BETHEL, Conn., Dec. 4 MedClean Technologies, Inc. ... a preferred stock purchase agreement with Socius Capital Group, LLC, a ... Capital Group, LLC. Pursuant to the Purchase Agreement, MedClean will receive ... to sell up to 750 shares of its Series C Preferred ...
... , UNION, N.J., Dec. 4 ... its specialty anatomic pathology services with the launch of ... company,s expansion from a regional laboratory to a leading ... full range of specialties including gastroenterology, urology and now ...
... , , OKLAHOMA CITY, Dec. 4 ... for the first quarter ended September 30, 2009, a 24% decrease ... income for the quarter were $133,681 and $80,402, respectively, each a ... impacted by a decrease in pharmacy sector sales. This trend ...
... , SEATTLE, Dec. 4 The National Cancer Institute ... Research Center to become the nation,s sole operator of its Cancer ... jobs at the Hutchinson Center - nearly tripling the size of ... operational, which is scheduled for March 15, 2010. The Seattle CIS ...
... Medicine (BUSM) researchers at the Slone Epidemiology Center found that ... reduced incidence of uterine leiomyomata (fibroids). This report, based on ... of the American Journal of Epidemiology . Uterine ... to three times more common among black women than white ...
... ... initiative to establish standards for language access in healthcare organizations. , ... Hudson, OH (PRWEB) ... solutions, and patient education materials for healthcare institutions, understands the importance of effective ...
Cached Medicine News:Health News:MedClean Technologies Enters Into Preferred Stock Agreement of Up to $7.5 Million 2Health News:MedClean Technologies Enters Into Preferred Stock Agreement of Up to $7.5 Million 3Health News:PLUS Diagnostics Launches Hematology/Oncology Diagnostic Services 2Health News:PLUS Diagnostics Launches Hematology/Oncology Diagnostic Services 3Health News:PD-Rx Pharmaceuticals, Inc. Reports 1st Quarter Earnings 2Health News:Hutchinson Center Wins $55.4 Million Contract to Become Sole Operator of the NCI Cancer Information Service 2Health News:Researchers find increased dairy intake reduces risk of uterine fibroids in black women 2Health News:Lexi-Comp Focused on Improving Patient Communication in Healthcare Institutions Treating Diverse Patient Populations 2Health News:Lexi-Comp Focused on Improving Patient Communication in Healthcare Institutions Treating Diverse Patient Populations 3
Full Handle Laseredge Slit Blade Knife, 3.0 mm straight. Blade tip dimension: 14.4 mm x 3.0 mm x 3.7 mm....
Full Handle Laseredge Slit Blade Knife, 2.85 mm angled bevel up. Blade tip dimension: 14.4 mm x 2.8 mm x 3.7 mm....
Full Handle Laseredge Slit Blade Knife, 2.8 mm angled double bevel. Blade tip dimension: N/A x 2.8 mm x N/A....
Full Handle Laseredge Slit Blade Knife, 2.5 mm angled bevel up. Blade tip dimension: 14.4 mm x 2.5 mm x 3.7 mm....
Medicine Products: